Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transfusions Clear all
Completed No phase listed Observational

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

NCT01913548
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Not listed
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
16 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
6
States / cities
Oakland, California • Augusta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 9, 2026, 5:40 AM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 9, 2026, 5:40 AM EDT
Recruiting Phase 2Phase 3 Interventional

Tranexamic Acid to Reduce Blood Loss in Spine Surgery

NCT02314988
View directory record Official record
Conditions
Spinal Injuries, Spinal Deformity
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
San Francisco, California • Louisville, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 9, 2026, 5:40 AM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of Stanate (TM) [Stannsoporfin]

NCT00076960
View directory record Official record
Conditions
Neonatal Jaundice, Hyperbilirubinemia
Interventions
Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
Drug
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
12 Hours to 1 Week
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

NCT02906202
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
LentiGlobin BB305 Drug Product
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00840827
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
lenalidomide, cyclosporine A
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 9, 2026, 5:40 AM EDT
Completed No phase listed Observational Results available

Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia

NCT01976442
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Up to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 9, 2026, 5:40 AM EDT
Recruiting No phase listed Observational

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

NCT03775954
View directory record Official record
Conditions
High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions
Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally
Diagnostic Test · Genetic
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

NCT01422486
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
ezatiostat hydrochloride (Telintra®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 9, 2026, 5:40 AM EDT
Completed No phase listed Observational

Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.

NCT00708513
View directory record Official record
Conditions
Pancreaticoduodenectomy, Pancreatectomy, Esophagectomy, Gastrectomy, Hepatectomy
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?

NCT02606058
View directory record Official record
Conditions
Preterm Birth
Interventions
Deferred cord clamping
Procedure
Lead sponsor
University of Sydney
Other
Eligibility
Female only
Enrollment
1,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Houston, Texas • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

NCT02604433
View directory record Official record
Conditions
Erythrocyte Transfusion, Beta-Thalassemia
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated No phase listed Observational

Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates

NCT01735552
View directory record Official record
Conditions
Anemia of Prematurity, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 12 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Age of Blood in Sickle Cell Transfusion

NCT03704922
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 9, 2026, 5:40 AM EDT
Enrolling by invitation No phase listed Observational

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

NCT06433622
View directory record Official record
Conditions
Traumatic Intracranial Hemorrhage
Interventions
Repeat Thromboelastography with Platelet Mapping
Diagnostic Test
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 9, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06763341
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, PCNA Inhibitor AOH1996, Venetoclax
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated Phase 1Phase 2 Interventional

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

NCT03933813
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions
Iron Sucrose
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Transfusion Medicine - Prevention of Bedside Errors

NCT00127556
View directory record Official record
Conditions
Blood Transfusion
Interventions
Label applied to blood bag
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

NCT00981370
View directory record Official record
Conditions
Anemia, Sickle Cell, Transfusion Hemosiderosis
Interventions
deferasirox
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 9, 2026, 5:40 AM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 9, 2026, 5:40 AM EDT
Withdrawn Phase 1 Interventional

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

NCT01197209
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad-REIC/Dkk-3
Biological
Lead sponsor
Momotaro-Gene Inc.
Industry
Eligibility
20 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 9, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00122317
View directory record Official record
Conditions
Paroxysmal Hemoglobinuria, Nocturnal
Interventions
eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Stanford, California • Hartford, Connecticut • Weston, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 9, 2026, 5:40 AM EDT